Tuesday, 3 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 03 March 2026
News

Govt funding fail costing $45B

Posted 3 March 2026 PM

Eli Lilly is pushing the case for wider government reimbursement of obesity medications with a new report from GlobalData indicating obesity and overweight is costing Australia $45 billion each year. 

The pharma giant is keen to extend funding for weight loss drugs beyond people with obesity and comorbidities to a wider population, banking on improving perception of its obesity drug Mounjaro. Last November the PBAC gave a recommendation to Novo Nordisk for Wegovy, for people with established cardiovascular disease with obesity, after failing twice to recommend the drug for obesity alone.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (10)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.